Arcturus Therapeutics Holdings Inc. (ARCT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Arcturus Therapeutics reported revenue of $82.0M, down 46.1% from $152.3M the year before. Net income was -$65.8M (a -80.2% net margin), or -$2.40 per diluted share. Operating margin was -93.0%. Operating activities generated -$74.3M of cash, leaving -$74.5M of free cash flow. At fiscal year end, Arcturus Therapeutics held $271.1M in total assets against $57.2M in total liabilities, including $230.9M of cash and equivalents.
Open the full interactive Arcturus Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Arcturus Therapeutics Key Stats
| Share Price | $12.03 |
|---|---|
| Market Cap | $341.9M |
| Revenue YoY Growth | -46.1% |
| 52-Week Range | $5.53 – $23.16 |
| Shares Outstanding | 28.4 million (basic, 2026 Q2) |
Arcturus Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $9.5M | $12.4M | $206.0M | $166.8M | $152.3M | $82.0M |
| Operating Income | -$71.5M | -$202.9M | $12.2M | -$78.2M | -$95.7M | -$76.3M |
| Pre-Tax Income | -$72.1M | -$203.7M | $10.6M | -$27.9M | $81.0M | -$65.8M |
| Income Tax | — | — | $1.3M | $1.8M | -$4,000 | — |
| Net Income | -$72.1M | -$203.7M | $9.3M | -$29.7M | -$80.9M | -$65.8M |
| Diluted EPS | -$3.55 | -$7.74 | $0.35 | -$1.12 | -$3.00 | -$2.40 |
Arcturus Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $17.2M | $7.2M | $2.1M | $3.0M |
| Net Income | -$13.4M | -$29.1M | -$27.0M | -$23.8M |
| Diluted EPS | -$0.49 | -$1.06 | -$0.95 | -$0.84 |
Arcturus Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $462.9M | $370.5M | $391.9M | $292.0M | $237.0M | $230.9M |
| Current Assets | $467.8M | $379.0M | $403.3M | $386.6M | $306.0M | $241.4M |
| Total Assets | $476.5M | $392.8M | $450.4M | $429.4M | $344.1M | $271.1M |
| Current Liabilities | $49.5M | $99.5M | $127.0M | $82.0M | $65.5M | $36.4M |
| Total Long-Term Debt | $15.1M | $63.1M | $60.7M | — | — | — |
| Total Liabilities | $79.9M | $164.6M | $180.1M | $150.9M | $103.1M | $57.2M |
| Shareholders' Equity | $396.6M | $228.2M | $270.3M | $278.5M | $241.0M | $214.0M |
Arcturus Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$42.9M | -$135.0M | $32.0M | -$18.1M | -$59.7M | -$74.3M |
| Cash From Investing | -$1.7M | -$3.4M | -$7.7M | -$2.9M | -$648,000 | -$230,000 |
| Cash From Financing | $436.1M | $48.0M | -$2.9M | -$24.1M | $5.4M | $13.4M |
| Free Cash Flow | -$44.6M | -$138.4M | $24.3M | -$21.0M | -$60.4M | -$74.5M |
Figures from Arcturus Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Arcturus Therapeutics financials page for every line item.
Arcturus Therapeutics Company Profile
| Ticker | ARCT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, smaller reporting company |
| SEC CIK | 0001768224 |
Frequently Asked Questions
What was Arcturus Therapeutics' revenue in fiscal 2025?
Arcturus Therapeutics (ARCT) reported revenue of $82.0M for fiscal 2025.
What is Arcturus Therapeutics' annual revenue history?
Arcturus Therapeutics' annual revenue by fiscal year: 2020: $9.5M; 2021: $12.4M; 2022: $206.0M; 2023: $166.8M; 2024: $152.3M; 2025: $82.0M.
What was Arcturus Therapeutics' net income in fiscal 2025?
Arcturus Therapeutics reported net income of -$65.8M for fiscal 2025.
What was Arcturus Therapeutics' earnings per share (EPS) in fiscal 2025?
Arcturus Therapeutics' diluted EPS was -$2.40 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Arcturus Therapeutics generate in fiscal 2025?
Arcturus Therapeutics generated -$74.5M of free cash flow in fiscal 2025.
What was Arcturus Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Arcturus Therapeutics reported revenue of $3.0M.
How many shares of Arcturus Therapeutics are outstanding?
Arcturus Therapeutics reported a weighted average of 28.4 million basic shares outstanding in 2026 Q2.
What is Arcturus Therapeutics' market cap?
Based on its latest closing price, Arcturus Therapeutics (ARCT) has a market capitalization of about $341.9M.
When does Arcturus Therapeutics' fiscal year end?
Arcturus Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Arcturus Therapeutics headquartered?
Arcturus Therapeutics lists its business address in San Diego, California in its SEC filings.